Senlmed

Senlmed is a clinical-stage biopharmaceutical company focused on developing innovative therapies that target cellular senescence to treat age-related and chronic diseases. Headquartered in Suzhou, China, the company utilizes a proprietary drug discovery platform to identify senolytic small molecules that selectively eliminate senescent cells, which are known to drive inflammation and tissue dysfunction. Its lead candidate, SNL-101, is currently in Phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond IPF, Senlmed is advancing a pipeline of candidates for indications such as osteoarthritis and chronic kidney disease. The company aims to address the fundamental biological drivers of aging to improve patient outcomes in degenerative conditions.